How have HEMO shares performed in 2024?

Hemogenyx Pharmaceuticals' stock was trading at GBX 2.30 on January 1st, 2024. Since then, HEMO stock has decreased by 30.0% and is now trading at GBX 1.61. View the best growth stocks for 2024 here .

How were Hemogenyx Pharmaceuticals' earnings last quarter?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) posted its quarterly earnings results on Wednesday, September, 30th. The company reported ($0.20) earnings per share for the quarter.

What other stocks do shareholders of Hemogenyx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hemogenyx Pharmaceuticals investors own include Avaya (AVYA) , Baidu (BIDU) , Corbus Pharmaceuticals (CRBP) , Curaleaf (CURLF) , Heat Biologics (HTBX) , Incyte (INCY) , InMode (INMD) , Intuitive Surgical (ISRG) and Remark (MARK) .

How do I buy shares of Hemogenyx Pharmaceuticals?

Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:HEMO

Hemogenyx Pharmaceuticals (HEMO) Share Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free HEMO Stock Alerts

GBX 1.61

+0.01 (+0.69%)

(As of 04:21 PM ET)

Compare

Today's Range: 1.58
▼
1.65
50-Day Range: 1.57
▼
4
52-Week Range: 1.10
▼
7.13

Volume: 3.32 million shs
Average Volume: 14.49 million shs
Market Capitalization: £21.57 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Headlines

Get Hemogenyx Pharmaceuticals alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Hemogenyx Pharmaceuticals Stock (LON:HEMO)

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

HEMO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HEMO Stock News Headlines

April 15, 2024 | msn.com

SMALL CAP IDEA: Why investors should add Hemogenyx Pharmaceuticals to their watchlist

March 30, 2024 | msn.com

Compare with Oxurion NV (0G99)

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

March 28, 2024 | finance.yahoo.com

Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

March 13, 2024 | proactiveinvestors.com

Albo unveils ambitious $4 billion plan to overhaul remote housing in the Northern Territory

March 12, 2024 | finance.yahoo.com

Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it advances HEMO-CAR-T program

February 29, 2024 | finance.yahoo.com

Hemogenyx Pharmaceuticals PLC Announces Placing to Raise US$4.2 million

February 21, 2024 | lse.co.uk

London pre-open: Stocks to nudge up; HSBC in focus

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

February 20, 2024 | finance.yahoo.com

Lung Cancer Research Foundation and American Lung Cancer Screening Initiative Join Forces for "Plus One" Campaign

February 20, 2024 | finance.yahoo.com

Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform

February 16, 2024 | lse.co.uk

Hemogenyx shares rise on potential for CBR to treat brain diseases

February 16, 2024 | finance.yahoo.com

Hemogenyx Pharmaceuticals PLC Announces CBR Brain Delivery

February 14, 2024 | finance.yahoo.com

Hemogenyx Pharmaceuticals PLC Announces CBR Intranasal Delivery

February 9, 2024 | finance.yahoo.com

Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T

February 2, 2024 | finance.yahoo.com

Hemogenyx Pharmaceuticals PLC Announces the Approval and Issuance of U.S. Conditioning Patent

January 16, 2024 | finance.yahoo.com

Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical Hold

January 8, 2024 | lse.co.uk

Hemogenyx Pharmaceuticals completes process qualification run

November 28, 2023 | finance.yahoo.com

Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £534,375

November 27, 2023 | lse.co.uk

Hemogenyx shares up as says CBR platform a potential cancer treatment

November 27, 2023 | marketwatch.com

HemoGenyx Says CBR Platform Could Potentially Be Used for Cancer Treatment

November 27, 2023 | finance.yahoo.com

Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer

November 15, 2023 | finance.yahoo.com

Hemogenyx Pharmaceuticals PLC Announces Lentivirus Re-manufacturing Completed

September 28, 2023 | lse.co.uk

EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens

September 18, 2023 | seekingalpha.com

Prevail Partners to invest in Hemogenyx Pharmaceuticals

September 18, 2023 | marketwatch.com

Hemogenyx Stock Rises on Premium Share Subscription

September 14, 2023 | marketwatch.com

Hemogenyx Pharmaceuticals Says FDA Accepted Plans to Address Leukemia Treatment Concerns

See More Headlines

Receive HEMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemogenyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 9/30/2020
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: LON:HEMO
Previous Symbol: LON:SILF
CUSIP: N/A
CIK: N/A
Web: silverfalconplc.com
Phone: 44 79 0917 7311
Fax: N/A
Employees: 14
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-7,170,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -136.44%
Return on Assets: -58.66%

Debt

Debt-to-Equity Ratio: 89.95
Current Ratio: 4.07
Quick Ratio: 6.72

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 1,340,000,000
Free Float: N/A
Market Cap: £21.57 million
Optionable: Not Optionable
Beta: 3.06

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Vladislav Sandler Ph.D. (Age 59)
Co-Founder, CEO & Director
Comp: $282k
Ms. Alexis M. Sandler J.D. (Age 48)
Independent Co-Founder & Non-Executive Director
Comp: $57k
Dr. Koen Van Besien M.D.
Ph.D., Clinical Advisor & Medical Director

Key Competitors

View All Competitors

HEMO Stock Analysis - Frequently Asked Questions

How have HEMO shares performed in 2024?: Hemogenyx Pharmaceuticals' stock was trading at GBX 2.30 on January 1st, 2024. Since then, HEMO stock has decreased by 30.0% and is now trading at GBX 1.61.
View the best growth stocks for 2024 here.
How were Hemogenyx Pharmaceuticals' earnings last quarter?: Hemogenyx Pharmaceuticals Plc (LON:HEMO) posted its quarterly earnings results on Wednesday, September, 30th. The company reported ($0.20) earnings per share for the quarter.
What other stocks do shareholders of Hemogenyx Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Hemogenyx Pharmaceuticals investors own include Avaya (AVYA), Baidu (BIDU), Corbus Pharmaceuticals (CRBP), Curaleaf (CURLF), Heat Biologics (HTBX), Incyte (INCY), InMode (INMD), Intuitive Surgical (ISRG) and Remark (MARK).
How do I buy shares of Hemogenyx Pharmaceuticals?: Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:HEMO) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial